From Medscape Diabetes & Endocrinology

Coverage from the

American Diabetes Association (ADA) 82nd Scientific Sessions

June 03 - 07, 2022; New Orleans, Louisiana and Virtual

June 03 - 07, 2022 New Orleans, Louisiana and Virtual

ADA 2022 Tirzepatide Powers 'Unprecedented' Weight Loss in Obesity Trial The twincretin tirzepatide produced jaw-dropping levels of weight loss in people with obesity and no diabetes compared with placebo in the SURMOUNT-1 pivotal trial with more than 2500 participants.
Medscape Medical News, June 4, 2022
ADA 2022 Will Tirzepatide Slow Kidney Function Decline in Type 2 Diabetes? Compared with insulin glargine, tirzepatide was associated with significantly less new-onset macroalbuminuria in patients with type 2 diabetes at high cardiovascular risk but mainly normal kidney function.
Medscape Medical News, June 3, 2022
ADA 2022 ADA Updates on Finerenone, SGLT2 Inhibitors, and Race-Based eGFR ADA has made an interim change to its latest Standards of Medical Care, an update based on trial evidence and consensus about finerenone, SGLT2 inhibitors, and eGFR.
Medscape Medical News, June 1, 2022

Conference News

ADA 2022 Menstrual Phase Impacts Exercise Effects in Type 1 Diabetes
Medscape Medical News, July 5, 2022
ADA 2022 Diabetes Tied to Risk of Long COVID, Too
Medscape Medical News, June 29, 2022
ADA 2022 2-Year Faricimab Results: 'Visual Gains With Fewer Injections'
Medscape Medical News, June 27, 2022
ADA 2022 Type 1 Diabetes Control Worse in Racially Segregated Teens
Medscape Medical News, June 24, 2022
ADA 2022 Glucagon Analog Stops Hypoglycemia Faster Than Carbs
Medscape Medical News, June 24, 2022
ADA 2022 New Data, Film Highlight Islet Cell Transplantation Progress
Medscape Medical News, June 23, 2022
ADA 2022 Best Albuminuria Drug for Diabetes Varies by Patient
Medscape Medical News, June 22, 2022
ADA 2022 Experts Elevate New Drugs for Diabetic Kidney Disease
Medscape Medical News, June 16, 2022
ADA 2022 Exercise of Any Type Boosts Type 1 Diabetes Time in Range
Medscape Medical News, June 16, 2022
ADA 2022 SGLT2 Inhibitors Cut AFib Risk in Real-World Analysis
Medscape Medical News, June 14, 2022
ADA 2022 Technology in Type 1 Diabetes Gets Patients Closer to Targets
Medscape Medical News, June 13, 2022
ADA 2022 Basaglar 'Copycat' Insulin for Diabetes Has Advantages Over Lantus
Medscape Medical News, June 13, 2022
ADA 2022 'DIY' Artificial Pancreas Systems Found to Be Safe, Effective
Medscape Medical News, June 10, 2022
ADA 2022 Self-Injury and Suicide 'All Too Common' in Type 1 Diabetes
Medscape Medical News, June 9, 2022

ADA 2022 Increased Hypoglycemia Not Seen With Once-Weekly Insulin?
Medscape Medical News, June 9, 2022
ADA 2022 Stem Cell Transplants Promising So Far in Type 1 Diabetes
Medscape Medical News, June 6, 2022
ADA 2022 Antidiabetes Drug Costs Keep Patients Away
Medscape Medical News, June 6, 2022
ADA 2022 Obesity in Adolescence Raises Risk for Adult Type 1 Diabetes
Medscape Medical News, June 6, 2022
ADA 2022 'Remission Is Possible' for Patients With Type 2 Diabetes
Medscape Medical News, June 6, 2022
ADA 2022 Weekly Dulaglutide Promising in Youth With Type 2 Diabetes
Medscape Medical News, June 5, 2022
ADA 2022 Tirzepatide Powers 'Unprecedented' Weight Loss in Obesity Trial
Medscape Medical News, June 4, 2022
ADA 2022 Bionic Pancreas: Closer to Fully Automated Insulin Delivery?
Medscape Medical News, June 4, 2022
ADA 2022 Will Tirzepatide Slow Kidney Function Decline in Type 2 Diabetes?
Medscape Medical News, June 3, 2022
ADA 2022 Bariatric Surgery Cuts Risk of Developing and Dying From Cancer
Medscape Medical News, June 3, 2022
ADA 2022 ADA Prioritizes Heart Failure in Patients With Diabetes
Medscape Medical News, June 2, 2022
ADA 2022 ADA Updates on Finerenone, SGLT2 Inhibitors, and Race-Based eGFR
Medscape Medical News, June 1, 2022
ADA 2022 ADA Scientific Sessions: Tirzepatide and Much More
Medscape Medical News, June 1, 2022

Medscape Diabetes© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Perspectives

What Is the Weight Impact of Type 2 Diabetes Treatment?
Priya Sumithran, PhD; Mark Harmel, MPH, CDCES
Do Sugary Drink Taxes Change Behavior?
Anna H. Grummon, PhD, MSPH; Mark Harmel, MPH, CDCES
Putting the Patient First: Top Insight From ADA 2022
Akshay B. Jain, MD
Let's Talk About Sex: Women With Diabetes Often Lose Interest
Sharon J. Parish, MD; Mark Harmel, MPH, CDCES
Put Down That Protein Bar and Opt for Nuts and Fruit Instead
Holly J. Willis, PhD, RDN, CDCES; Mark Harmel, MPH, CDCES
Turn 'Patients Into Experts' on Their Diabetes With CGM Use
Eden Miller, DO; Mark Harmel, MPH, CDCES
How Does Exercise Affect Type 1 Diabetes?
Michael C. Riddell, PhD; Mark Harmel, MPH, CDCES
Key Data on Insulin in Type 2 Diabetes From ADA 2022
George Grunberger, MD
Glycemic Control in Type 2 Diabetes From ADA 2022
Ildiko Lingvay, MD, MPH
Key Studies on Diabetes Comorbidities From ADA 2022
Anastassios G. Pittas, MD
'Not Their Fault': Obesity Warrants Long-term Management
Ania Jastreboff, MD, PhD
National Clinical Care Commission offers T2D Recommendations
William H. Herman, MD, MPH; Mark Harmel, MPH, CDCES
More Holistic Approach Needed for Hyperglycemia Management
John B. Buse, MD, PhD; Mark Harmel, MPH, CDCES
New Advances in Obesity Management, but Challenges Remain
Donna H. Ryan, MD; Mark Harmel, MPH, CDCES
Managing Chronic Kidney Disease in Patients With Diabetes
Sylvia Rosas, MD, MSCE; Mark Harmel, MPH
Insulin Cap Legislation: Addressing the Challenges of Access
Irl Hirsch, MD; Mark Harmel, MPH, CDCES

Popular News from ADA 2020

What's Best for Diabetes After Metformin? GRADE Outdated at Outset The GRADE trial compared four different agents as add-ons to metformin for type 2 diabetes, and while liraglutide and insulin glargine fared best, the study is already outdated, said one commentator.
Medscape Medical News, Jun 30, 2021
'Staggering' Doubling of Type 2 Diabetes in Kids During Pandemic Two new studies show a shocking increase in type 2 diabetes among kids in the US during the pandemic, with increased severity at presentation. Black children were disproportionately affected.
Medscape Medical News, Jun 26, 2021
Time-Restricted Eating Is 'Promising, But More Data Are Needed' 'I think time-restricted eating is promising because of its simple message and noted weight loss benefit, yet more data are needed,' said an expert.
Medscape Medical News, Jun 26, 2021

Previous Coverage